Chemotherapy-Induced Cardiotoxicity

  title={Chemotherapy-Induced Cardiotoxicity},
  author={Amir Y. Shaikh and Jeffrey A. Shih},
  journal={Current Heart Failure Reports},
Anthracycline-based chemotherapeutics have long been recognized as effective agents for treating a wide range of malignancies. However, their use is not without significant adverse cardiotoxic side effects. Strategies for prevention involve limiting free-radical production and subsequent cardiac myocyte damage. Dexrazoxane remains the most widely studied cardioprotective medication. Alternative agents may reduce cardiotoxicity but may still cause significant cardiovascular problems. The role of… 

Update on pathophysiology and preventive strategies of anthracycline‐induced cardiotoxicity

The clinical course, pathogenesis, cardiac monitoring and new concepts in diagnosing and preventing anthracycline‐induced cardiotoxicity are reviewed.

Association of Cardiotoxicity With Doxorubicin and Trastuzumab: A Double-Edged Sword in Chemotherapy

The role and mechanism of major chemotherapy agents with principal cardiovascular complications in cancer patients, including chemotherapy and radiation therapy, are discussed.

Role of Exogenous Phosphocreatine in Chemotherapy-induced Cardiomyopathy.

A 52-year-old woman with cardiomyopathy following chemotherapy and radiation therapy is reported on, who did not respond well to b-blockers and angiotensin-converting enzyme inhibitors, and whose cardiac condition improved significantly after the addition of exogenous phosphocreatine.

Cardiotoxicity and Chemotherapy—The Role of Precision Medicine

Cardiotoxicity and systemic anticancer therapy, with a focus on chemotherapy is discussed, and the challenge of identifying those at risk and the role of precision medicine as they strive for a personalised approach to this clinical scenario is discussed.

Cardiotoxicity associated with targeted cancer therapies (Review)

These most commonly used drugs and associated incidence of cardiotoxicities, including left ventricular dysfunction, heart failure, hypertension and thromboembolic events are discussed and their respective molecular mechanisms of cardiovascular adverse effects are summarized.

Duxorubicin-induced cardiotoxicity -

Clinically, anthracycline induced cardiotoxicity manifests itself as left ventricular failure, which develops insidiously over months to years after completion of the anthrACYcline based chemotherapy and may result in congestive HF, and the mechanism is likely that the decline in myocardial function is related to apoptosis of cardiac myocytes that occurs apparently at random in the myocardium.

Cardiotoxicity Induced by Protein Kinase Inhibitors in Patients with Cancer

Common cardiotoxic effects of KIs are summarized, including hypertension, arrhythmias with bradycardia and QTc prolongation, and cardiomyopathy that can lead to heart failure, as well as less common effects such as fluid retention, ischemic heart disease, and elevated risk of thromboembolic events.

Anthracycline-Induced Cardiotoxicity: Causes, Mechanisms, and Prevention.

This chapter summarizes the identified mechanisms that may play a role in anthracycline-induced cardiotoxicity and the types of cardiomyopathies that have been described in survivors treated with doxorubicin and the current recommendations for monitoring survivor for the development of cardiologistopathies.

Role of Myocardial Strain Imaging in Chemotherapy Related Cardiotoxicity

A review elaborating the role of myocardial strain imaging in chemotherapy related cardiotoxicity is presented, with an increasing emphasis on earlier and more accurate prediction of cardiot toxicity using imaging modalities besides evaluation of LVEF.



Chemotherapy‐induced cardiotoxicity: current practice and prospects of prophylaxis

Anticancer therapy induced cardiotoxicity: review of the literature

The diagnostic work-up, the cardiotoxic risk of anthracyclines and trastuzumab, and additionally, cardiotoxicity as a risk factor of a multimodal therapeutic approach in breast cancer patients is discussed in this study.

Cancer Therapy-Associated Cardiotoxicity and Signaling in the Myocardium

The role of endothelial-myocardial communication in maintaining phenotype and survival of adult cardiomyocytes has increasingly been recognized and has demonstrated the importance of the ErbB/neuregulin signaling system in the adult heart.

Anthracycline-induced cardiotoxicity.

Modification of dosage schedule and synthesis of new anthracycline analogues may represent alternative approaches to mitigate anthrACYcline cardiotoxicity while preserving antitumour activity.

Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management.

The cardiotoxicity of anticancer agents can lead to significant complications that can affect patients being treated for various malignancies. The severity of such toxicity depends on many factors

Mechanisms of anthracycline cardiac injury: can we identify strategies for cardioprotection?

Role of biomarkers in cardioncology

The role of troponin I in identifying patients at risk of cardiotoxicity and of angiotensin-converting enzyme inhibitors in preventing left ventricular ejection fraction reduction and late cardiac events represent an effective tool for the prevention of this complication.

Clinical management of doxorubicin-induced heart failure.

Surgical procedures for Doxorubicin-induced heart failure are presented and their efficacy as well as their clinical applicability are discussed.

Doxorubicin‐induced cardiomyopathy treated with carvedilol

The first case of a patient complaining of severe symptoms of congestive heart failure due to doxorubicin‐induced dilated cardiomyopathy unresponsive to standard medical treatment is described, who showed complete clinical recovery and significant improvement of left ventricular dysfunction after carvedilol treatment.

Dexrazoxane : a review of its use for cardioprotection during anthracycline chemotherapy.

The cardioprotective efficacy of dexrazoxane in patients with childhood malignancies is supported by limited data, and the drug is generally well tolerated and has a tolerability profile similar to that of placebo in cancer patients undergoing anthracycline-based chemotherapy.